Etavopivat

Etavopivat
Clinical data
Other names	FT-4202; NN 7535; NN-7536; NN7535
Legal status
Legal status	investigational;
Identifiers
	IUPAC name (2S)-1-[5-(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-ylsulfonyl)-1,3,4,6-tetrahydropyrrolo[3,4-c]pyrrol-2-yl]-3-hydroxy-2-phenylpropan-1-one;
CAS Number	2245053-57-8;
PubChem CID	135338378;
IUPHAR/BPS	11975;
DrugBank	DB18176;
ChemSpider	115009606;
UNII	V4E0A9M44Q;
KEGG	D12362;
ChEBI	CHEBI:758230;
ChEMBL	ChEMBL4650332;
Chemical and physical data
Formula	C22H23N3O6S
Molar mass	457.50 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1COC2=C(O1)C=C(C=N2)S(=O)(=O)N3CC4=C(C3)CN(C4)C(=O)[C@H](CO)C5=CC=CC=C5;
	InChI InChI=InChI=1S/C22H23N3O6S/c26-14-19(15-4-2-1-3-5-15)22(27)24-10-16-12-25(13-17(16)11-24)32(28,29)18-8-20-21(23-9-18)31-7-6-30-20/h1-5,8-9,19,26H,6-7,10-14H2/t19-/m1/s1; Key:KZFFYEPYCVDOGE-LJQANCHMSA-N;

Etavopivat is an investigational new drug that is being evaluated by FORMA Therapeutics for the treatment of sickle cell disease and thalassemia. It is an allosteric activator of the erythrocyte pyruvate kinase R (PKR) enzyme.^[1]^[2]^[3]

Clinical trials

Etavopivat is in phase 3 clinical trials for sickle cell disease and thalassemia.^[4]

↑ "Etavopivat - FORMA Therapeutics". AdisInsight. Springer Nature Switzerland AG.
↑ Matte A, Federti E, De Franceschi L (May 2023). "Erythrocyte pyruvate kinase activation in red cell disorders". Current Opinion in Hematology. 30 (3): 93–98. doi:10.1097/MOH.0000000000000758. PMID 36853806.
↑ Musallam KM, Andemariam B (June 2026). "Pyruvate Kinase Activation in the Management of Thalassemia and Sickle Cell Disease". Hemoglobin: 1–13. doi:10.1080/03630269.2026.2682386. PMID 42261266.
↑ Clinical trial number NCT06609226 for "A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia" at ClinicalTrials.gov